GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Haw Par Corp Ltd (OTCPK:HAWPF) » Definitions » YoY EBITDA Growth

Haw Par (Haw Par) YoY EBITDA Growth : 54.28% (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Haw Par YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Haw Par's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 54.28%.

Haw Par's EBITDA per Share for the six months ended in Dec. 2023 was $0.42.


Haw Par YoY EBITDA Growth Historical Data

The historical data trend for Haw Par's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haw Par YoY EBITDA Growth Chart

Haw Par Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.35 -34.61 -8.33 35.63 45.65

Haw Par Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100.00 39.20 26.89 38.99 54.28

Haw Par YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Haw Par's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(0.804-0.552)/ | 0.552 |
=45.65 %

Haw Par's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (Q: Dec. 2023 )
=(EBITDA per Share (Q: Dec. 2023 )-EBITDA per Share (Q: Dec. 2022 )) / | EBITDA per Share (Q: Dec. 2022 )) |
=(0.415-0.269)/ | 0.269 |
=54.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Haw Par YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Haw Par's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Haw Par (Haw Par) Business Description

Traded in Other Exchanges
Address
401 Commonwealth Drive, No. 03-03 Haw Par Technocentre, Singapore, SGP, 149598
Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, and Others segment. The company generates maximum revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates a majority of its revenue from the ASEAN countries.

Haw Par (Haw Par) Headlines

From GuruFocus

Singapore Based Haw Par Selling at a Discount to NAV

By Holmes Osborne, CFA Holmes Osborne, CFA 07-26-2016

Haw Par Stock Is Believed To Be Significantly Overvalued

By GF Value GF Value 03-31-2021

First Eagle Comments on Haw Par

By Holly LaFon Holly LaFon 04-24-2018